Research Article
Prognostic Value of Inflammatory and Tumour Markers in Small-Duct Subtype Intrahepatic Cholangiocarcinoma after Curative-Intent Resection
Table 5
Association of PII and ferritin with demographic and clinicopathological characteristics in small-duct type ICC of training cohort.
| | Variables | PII | Ferritin | | Low | High | value | Low | High | value |
| | Age (years) | | | 0.289 | | | 0.032 | | <65 | 52 (81.3%) | 12 (18.8%) | | 16 (27.6%) | 42 (72.4%) | | | ≥65 | 15 (93.8%) | 1 (6.3%) | | 9 (56.3%) | 7 (43.8%) | | | Gender | | | 0.711 | | | 0.015 | | Male | 39 (84.8%) | 7 (15.2%) | | 10 (22.7%) | 34 (77.3%) | | | Female | 28 (82.4%) | 6 (17.6%) | | 15 (50.0%) | 15 (50.0%) | | | INR | | | 0.025 | | | 0.026 | | <1.0 | 43 (91.5%) | 4 (8.5%) | | 19 (44.2%) | 24 (55.8%) | | | ≥1.0 | 24 (72.7%) | 9 (27.3%) | | 6 (19.4%) | 25 (80.6%) | | | ALT (U/L) | | | 0.069 | | | 0.019 | | <40 | 54 (88.5%) | 7 (11.5%) | | 23 (41.1%) | 33 (58.9%) | | | ≥40 | 13 (68.4%) | 6 (31.6%) | | 2 (11.1%) | 16 (88.9%) | | | Albumin (g/L) | | | 0.115 | | | 0.279 | | <43 | 20 (74.1%) | 7 (25.9%) | | 7 (25.9%) | 20 (74.1%) | | | ≥43 | 47 (88.7%) | 6 (11.3%) | | 18 (38.3%) | 29 (61.7%) | | | TBIL (umol/L) | | | 0.052 | | | 0.024 | | <21 | 61 (87.1%) | 9 (12.9%) | | 25 (38.5%) | 40 (61.5%) | | | ≥21 | 6 (60.0%) | 4 (40.0%) | | 0 (0.0%) | 9 (100.0%) | | | GGT (U/L) | | | 0.043 | | | 0.001 | | <45 | 36 (92.3%) | 3 (7.7%) | | 19 (52.8%) | 17 (47.2%) | | | ≥45 | 31 (75.6%) | 10 (24.4%) | | 6 (15.8%) | 32 (84.2%) | | | ALP (U/L) | | | 0.005 | | | 0.197 | | <135 | 60 (89.6%) | 7 (10.4%) | | 19 (52.8%) | 17 (47.2%) | | | ≥135 | 7 (53.8%) | 6 (46.2%) | | 6 (15.8%) | 32 (84.2%) | | | Histological grade | | | 0.328 | | | 0.254 | | G1-G2 | 36 (80.0%) | 9 (20.0%) | | 16 (40.0%) | 24 (60.0%) | | | G3 | 30 (88.2%) | 4 (11.8%) | | 9 (27.3%) | 24 (72.7%) | | | Vascular invasion | | | 0.011 | | | 0.293 | | Negative | 40 (93.0%) | 3 (7.0%) | | 16 (40.0%) | 24 (60.0%) | | | Positive | 25 (71.4%) | 10 (28.6%) | | 9 (28.1%) | 23 (71.9%) | | | Satellite lesions | | | 1.000 | | | 0.411 | | Negative | 59 (83.1%) | 12 (16.9%) | | 24 (35.8%) | 43 (64.2%) | | | Positive | 8 (88.9%) | 1 (11.1%) | | 1 (14.3%) | 6 (85.7%) | | | category | | | 0.015 | | | 0.040 | | | 35 (94.6%) | 2 (5.4%) | | 16 (45.7%) | 19 (54.3%) | | | | 32 (74.4%) | 11 (25.6%) | | 9 (23.1%) | 30 (76.9%) | | | category | | | 1.000 | | | 0.119 | | | 23 (76.7%) | 7 (23.3%) | | 12 (42.9%) | 16 (57.1%) | | | | 7 (77.8%) | 2 (22.2%) | | 1 (11.1%) | 8 (88.9%) | | | category | | | 0.417 | | | 0.320 | | | 65 (84.4%) | 12 (15.6%) | | 25 (35.2%) | 46 (64.8%) | | | | 2 (66.7%) | 1 (33.3%) | | 0 (0.0%) | 3 (100.0%) | | | TNM stage | | | 0.669 | | | 0.065 | | I-II | 23 (79.3%) | 6 (20.7%) | | 12 (44.4%) | 15 (55.6%) | | | III-IV | 7 (70.0%) | 3 (30.0%) | | 1 (10.0%) | 9 (90.0%) | |
|
|
